Controlling the spread of carbapenemase-producing Gram-negatives: therapeutic approach and infection control.
about
Epidemiology of carbapenemase-producing Enterobacteriaceae and Acinetobacter baumannii in Mediterranean countriesThe Widespread Presence of a Multidrug-Resistant Escherichia coli ST131 Clade among Community-Associated and Hospitalized PatientsCarbapenem-Resistant Enterobacteriaceae: A Strategic Roadmap for Infection Control.Prevalence and emergence of carbapenemases-producing Gram-negative bacteria in Mediterranean basin.The changing burden of infectious disease in Europe.The Immaculate Carbapenemase Study.Hospital epidemiology and infection control in acute-care settings.Retrospective analysis of fosfomycin combinational therapy for sepsis caused by carbapenem-resistant Klebsiella pneumoniae.Molecular and epidemiological characterization of IMP-type metallo-β-lactamase-producing Enterobacter cloacae in a Large tertiary care hospital in Japan.Epidemiology and clinical outcomes of patients with carbapenem-resistant Klebsiella pneumoniae bacteriuria.A call for action: the application of The International Health Regulations to the global threat of antimicrobial resistance.Comparison of BD Phoenix, Vitek 2, and MicroScan automated systems for detection and inference of mechanisms responsible for carbapenem resistance in Enterobacteriaceae.Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections.Containment of a country-wide outbreak of carbapenem-resistant Klebsiella pneumoniae in Israeli hospitals via a nationally implemented intervention.Risk factors for bacteriuria with carbapenem-resistant Klebsiella pneumoniae and its impact on mortality: a case-control study.Carbapenem-resistant Enterobacteriaceae: biology, epidemiology, and management.New Delhi metallo-β-lactamase-1 in Enterobacteriaceae: emerging resistance.Efficacy of admission screening for extended-spectrum beta-lactamase producing EnterobacteriaceaeNew Delhi metallo-β-lactamase-1: local acquisition in Ontario, Canada, and challenges in detection.Evaluation of a new phenotypic OXA-48 disk test for differentiation of OXA-48 carbapenemase-producing Enterobacteriaceae clinical isolates.Nosocomial outbreak of VIM-1-producing Klebsiella pneumoniae isolates of multilocus sequence type 15: molecular basis, clinical risk factors, and outcome.Emergence of New Delhi metallo-beta-lactamase (NDM-1) and Klebsiella pneumoniae carbapenemase (KPC-2) in South Africa.Impact of combination antimicrobial therapy on mortality risk for critically ill patients with carbapenem-resistant bacteremia.Characterization and Clinical Impact of Bloodstream Infection Caused by Carbapenemase-Producing Enterobacteriaceae in Seven Latin American Countries.Comparative evaluation of a prototype chromogenic medium (ChromID CARBA) for detecting carbapenemase-producing Enterobacteriaceae in surveillance rectal swabs.Carbapenemase-Producing Klebsiella pneumoniae, a Key Pathogen Set for Global Nosocomial DominanceOXA-163-producing Klebsiella pneumoniae in Cairo, Egypt, in 2009 and 2010.Klebsiella pneumoniae bloodstream infection: epidemiology and impact of inappropriate empirical therapy.Imported Klebsiella pneumoniae carbapenemase-producing K. pneumoniae clones in a Greek hospital: impact of infection control measures for restraining their dissemination.Understanding the molecular determinants of substrate and inhibitor specificities in the Carbapenemase KPC-2: exploring the roles of Arg220 and Glu276.Development of an algorithm for phenotypic screening of carbapenemase-producing Enterobacteriaceae in the routine laboratoryDevelopment of selective medium for IMP-type carbapenemase-producing Enterobacteriaceae in stool specimensCarbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensionsA Two-Year Surveillance in Five Colombian Tertiary Care Hospitals Reveals High Frequency of Non-CG258 Clones of Carbapenem-Resistant Klebsiella pneumoniae with Distinct Clinical CharacteristicsIs patient isolation the single most important measure to prevent the spread of multidrug-resistant pathogens?The rise of carbapenem resistance in Europe: just the tip of the iceberg?Bibliometric analysis of global scientific research on carbapenem resistance (1986-2015)The clinical impact of multidrug-resistant gram-negative bacilli in the management of septic shock.Global spread of drug-resistant Acinetobacter baumannii: molecular epidemiology and management of antimicrobial resistance.Status report on carbapenemases: challenges and prospects.
P2860
Q26827160-08D7BADF-8325-4FB2-A668-1B4E51298571Q28550451-38DF3BF2-DCF0-45BC-958F-233521F678E5Q30148824-B5F8FB54-0604-492C-896E-4D5DCE46FF61Q30249131-0173030D-51C2-4BA3-AF26-F351B4A62B8AQ30318298-1BF76BF8-9349-4507-B6C6-9B54D1AC45BEQ30401027-E93B18F4-77D7-432C-8BA0-C29B91D5AEA8Q30429049-EE871470-7FFC-4A22-8AAF-B86A958EB8ADQ33597689-C9006071-5A32-4BC5-8DED-20AA419DCE46Q33797958-3B18B610-433E-4D21-9B27-1CDC43B11B3AQ33798101-33F61832-693F-4797-9F3C-C499F919C86BQ33883793-DAA498A4-0AE2-473F-AA20-1A7F875CDD1EQ34046522-9CE088DD-3334-4F42-ACB7-1C9F11337284Q34057425-AAA1EFEF-009B-453A-98B3-EBBDDC74FDDCQ34164279-20BAEE48-CC92-493B-8F76-1BAE2296954CQ34319838-F3C9E810-908C-4085-9F51-8ACADB27750BQ34437229-0F02ABE9-3CB4-41DA-A636-7A9032001CE7Q34472466-A9C02F9D-08D6-4A6E-8376-73CC6DBB69EAQ34701924-E218F926-8CC2-4B40-833F-D576A0C2B7E4Q35156629-E90D043D-ABE9-45D9-A729-C6E1F65F1722Q35193334-A1AD8013-E633-44F3-873A-DD339800C42AQ35666523-CF6B1AF3-E8E0-4313-89DB-3EC34DDF0E15Q35689153-889B6903-83EC-43D1-A245-B5CD334B665BQ35746258-EA455532-B0A6-47AE-9E71-1EAF7D94EC58Q35996924-D8F10A24-D3DB-4717-8586-5E9372D2B4CFQ36022864-5989A7E4-F360-4E81-B0AC-F66B1DBE6D4FQ36076066-9018E0CD-1EA8-43B0-8370-C79C95E45FA2Q36118665-50A80E92-E983-4B42-AB4B-8CDDAD60AAF7Q36150730-3F65F4C1-8F60-4230-9F9E-25479787C169Q36171353-7BBA315F-1A09-469E-B844-D55076972DE2Q36171576-CC22E2F5-FC2A-48C3-96F6-3BBC4BF94E52Q36251716-FDD69C7F-93B5-42C2-A6DE-B425A7A90DF4Q36322444-286B8D00-A847-43FC-AD66-0F0DFE7132D0Q36361921-583FE020-F819-427E-87C2-4B94FF0A70BFQ36438958-198F723A-87A1-47F3-BB84-925BCC4481ACQ36845885-DA230CD2-708F-48C3-80FC-A718B386FC57Q36952815-CE69521A-4384-42F2-9E4E-D17674B2FF36Q37280844-CEB1F98D-7BD1-432B-A8A3-E3FE38139E84Q37563005-6DAEE987-97A7-4749-92E9-9946AA269EABQ37869910-3651872C-3DCB-4185-98D0-EF374D10EDC3Q37879199-22C21E30-306C-4D48-9B8E-1BE7535CEF30
P2860
Controlling the spread of carbapenemase-producing Gram-negatives: therapeutic approach and infection control.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Controlling the spread of carb ...... pproach and infection control.
@en
Controlling the spread of carb ...... pproach and infection control.
@nl
type
label
Controlling the spread of carb ...... pproach and infection control.
@en
Controlling the spread of carb ...... pproach and infection control.
@nl
prefLabel
Controlling the spread of carb ...... pproach and infection control.
@en
Controlling the spread of carb ...... pproach and infection control.
@nl
P2093
P50
P1476
Controlling the spread of carb ...... approach and infection control
@en
P2093
P304
P356
10.1111/J.1469-0691.2009.03115.X
P577
2010-02-01T00:00:00Z